Rapt Therapeutics Stock Analysis
| RAPT Stock | USD 1.08 0.03 2.86% |
RAPT Therapeutics is undervalued with Real Value of 11.22 and Target Price of 41.67. The main objective of RAPT Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what RAPT Therapeutics is worth, separate from its market price. There are two main types of RAPT Therapeutics' stock analysis: fundamental analysis and technical analysis.
The RAPT Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. RAPT Therapeutics is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. RAPT Stock trading window is adjusted to America/New York timezone.
RAPT |
RAPT Stock Analysis Notes
About 87.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.4. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. RAPT Therapeutics recorded a loss per share of 2.78. The entity had not issued any dividends in recent years. The firm had 21:1 split on the December 14, 2010. RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. Rapt Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 88 people. To find out more about RAPT Therapeutics contact Brian MD at 650 489 9000 or learn more at https://www.rapt.com.RAPT Therapeutics Investment Alerts
| RAPT Therapeutics generated a negative expected return over the last 90 days | |
| RAPT Therapeutics has high historical volatility and very poor performance | |
| RAPT Therapeutics has some characteristics of a very speculative penny stock | |
| RAPT Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (116.8 M) with profit before overhead, payroll, taxes, and interest of 1.53 M. | |
| RAPT Therapeutics currently holds about 207.34 M in cash with (97.05 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.99, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 87.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: RAPT Therapeutics Analysts Recent Ratings Changes |
RAPT Therapeutics Upcoming and Recent Events
| 12th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
RAPT Largest EPS Surprises
Earnings surprises can significantly impact RAPT Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-03-11 | 2020-12-31 | -0.59 | -0.52 | 0.07 | 11 | ||
2020-08-13 | 2020-06-30 | -0.58 | -0.51 | 0.07 | 12 | ||
2023-05-11 | 2023-03-31 | -0.68 | -0.76 | -0.08 | 11 |
RAPT Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 683.2 K | State Street Corp | 2024-06-30 | 671.8 K | Euclidean Capital Llc | 2024-09-30 | 657.9 K | Alphabet Inc | 2024-09-30 | 540.3 K | Point72 Asset Management, L.p. | 2024-09-30 | 525.2 K | Two Sigma Investments Llc | 2024-09-30 | 520.4 K | Redmile Group, Llc | 2024-09-30 | 504.5 K | Cormorant Asset Management, Llc | 2024-09-30 | 496.8 K | Goldman Sachs Group Inc | 2024-06-30 | 373.8 K | Fmr Inc | 2024-09-30 | 5.2 M | Vanguard Group Inc | 2024-09-30 | 3.2 M |
RAPT Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 37.75 M.RAPT Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.67) | (0.71) | |
| Return On Capital Employed | (0.84) | (0.88) | |
| Return On Assets | (0.67) | (0.71) | |
| Return On Equity | (0.79) | (0.83) |
Management Efficiency
RAPT Therapeutics has return on total asset (ROA) of (0.4658) % which means that it has lost $0.4658 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8013) %, meaning that it created substantial loss on money invested by shareholders. RAPT Therapeutics' management efficiency ratios could be used to measure how well RAPT Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.71 in 2024. Return On Capital Employed is likely to drop to -0.88 in 2024. Total Current Liabilities is likely to drop to about 11.7 M in 2024. Liabilities And Stockholders Equity is likely to drop to about 151.1 M in 2024| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.84 | 2.88 | |
| Tangible Book Value Per Share | 3.84 | 2.88 | |
| Enterprise Value Over EBITDA | (7.25) | (7.61) | |
| Price Book Value Ratio | 6.48 | 6.80 | |
| Enterprise Value Multiple | (7.25) | (7.61) | |
| Price Fair Value | 6.48 | 6.80 | |
| Enterprise Value | 883.8 M | 522.4 M |
Effective leadership at RAPT Therapeutics drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Beta 0.324 | Return On Assets (0.47) | Return On Equity (0.80) |
Technical Drivers
As of the 25th of November, RAPT Therapeutics holds the Variance of 68.12, market risk adjusted performance of (0.25), and Mean Deviation of 5.57. Concerning fundamental indicators, the technical analysis model allows you to check practical technical drivers of RAPT Therapeutics, as well as the relationship between them.RAPT Therapeutics Price Movement Analysis
The output start index for this execution was two with a total number of output elements of fifty-nine. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. RAPT Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for RAPT Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
RAPT Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific RAPT Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on RAPT Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases RAPT Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
RAPT Therapeutics Outstanding Bonds
RAPT Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. RAPT Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most RAPT bonds can be classified according to their maturity, which is the date when RAPT Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| US75383KAA25 Corp BondUS75383KAA25 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
RAPT Therapeutics Predictive Daily Indicators
RAPT Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of RAPT Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
RAPT Therapeutics Forecast Models
RAPT Therapeutics' time-series forecasting models are one of many RAPT Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary RAPT Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About RAPT Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how RAPT Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling RAPT shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as RAPT Therapeutics. By using and applying RAPT Stock analysis, traders can create a robust methodology for identifying RAPT entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (63.14) | (59.98) | |
| Operating Profit Margin | (64.61) | (61.38) | |
| Net Loss | (61.67) | (58.58) | |
| Gross Profit Margin | (0.96) | (0.92) |
Current RAPT Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. RAPT analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. RAPT analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 41.67 | Buy | 12 | Odds |
Most RAPT analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand RAPT stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of RAPT Therapeutics, talking to its executives and customers, or listening to RAPT conference calls.
RAPT Stock Analysis Indicators
RAPT Therapeutics stock analysis indicators help investors evaluate how RAPT Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading RAPT Therapeutics shares will generate the highest return on investment. By understating and applying RAPT Therapeutics stock analysis, traders can identify RAPT Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 38.9 M | |
| Common Stock Shares Outstanding | 38.3 M | |
| Total Stockholder Equity | 147 M | |
| Property Plant And Equipment Net | 7.7 M | |
| Cash And Short Term Investments | 158.9 M | |
| Cash | 47.5 M | |
| Accounts Payable | 5.2 M | |
| Net Debt | -40.6 M | |
| 50 Day M A | 1.8432 | |
| Total Current Liabilities | 21.8 M | |
| Other Operating Expenses | 127.1 M | |
| Non Current Assets Total | 11.5 M | |
| Non Currrent Assets Other | 3.9 M | |
| Stock Based Compensation | 17.1 M |
Additional Tools for RAPT Stock Analysis
When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.